Liposome Drug Delivery Market Overview
The global Liposome Drug Delivery Market size is projected to reach a CAGR of 9.8% from 2023-2030.
Liposome drug delivery is a way of administering a medication that increases its bioavailability and reduces toxicity. Liposomes are tiny vesicles made from naturally occurring molecules in the body, which can transport drugs into targeted cells for improved effectiveness while reducing side effects compared to conventional methods like intravenous injections or oral medications. The Liposome-mediated drug delivery technology is one of the most promising approaches to treating cancers and other diseases.
The growth of the market can be attributed to the rising prevalence of cancer, and therefore the need for advanced drug delivery systems for the treatment of the disease. the rising focus of healthcare researchers on developing targeted drug delivery systems (TDDS) is also expected to create numerous opportunities for market growth. Furthermore, the factors that will enhance the growth of the market are the Growing geriatric population base across the world, high unmet medical needs owing to the increasing number of drug-resistant diseases, and increased use of liposomes for therapeutic purposes due to their advantages over other delivery systems such as injection, oral pill formulations.
On the other hand, High production cost is the major reason behind the hindrance of market growth. Additionally, low solubility and short half-life of liposomes can negatively affect the preference rate, hindering the growth of the Liposomes Drug Delivery Market.
Get a Sample Copy of the Liposome Drug Delivery Market Research Report (Use Corporate Email ID to Get Higher Priority): https://www.delvens.com/get-free-sample/liposome-drug-delivery-market
An increase has been witnessed in the demand for medical supplies to take care of the infected population. Respiratory support devices such as atomizers, life support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. The need for medical supplies has increased significantly among both healthcare professionals and the civil population for precautionary measures, owing to the rise in the number of COVID-19 cases worldwide. Manufacturers of these products have a chance to capitalize on this increased demand for medical supplies to ensure an adequate and continuous supply of personal protective equipment in the market. Therefore, COVID-19 is expected to have a significant impact on the global liposome drug delivery market.
Delvens Industry Expert's Standpoint
In the upcoming years, the desire for targeted drug delivery, the prevalence of chronic illnesses, and developments in liposome technology are projected to generate a large increase in the market for liposome drug delivery. Although there are many businesses operating in the industry, which is extremely fragmented, it is also fiercely competitive, with a few significant firms controlling the majority of the market share. The market is anticipated to be dominated by North America and Europe, but the Asia-Pacific region is anticipated to have considerable growth because of increased healthcare spending and the prevalence of chronic illnesses there. Johnson & Johnson, Pfizer, Inc., Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd. are a few of the market's top competitors. In the upcoming years, consolidation is predicted to continue as bigger competitors buy smaller rivals to broaden their product lines and boost their market share.
Key Findings
- The product segment is further fragmented into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. liposomal doxorubicin accounted for the largest share and is anticipated to maintain its dominance over the forecast period owing to the high efficacy of the drug exhibited in the treatment of cancer. Moreover, liposomal doxorubicin is beneficial over its traditional counterpart in terms of toxicity and targeted drug delivery.
- The technology segment is further fragmented into Stealth Liposome Technology, Non-PEGylated Liposome Technology, DepoFoam Liposome Technology, and Lysolipid Thermally Sensitive Liposome (LTSL) Technology. The stealth liposome technology segment held the largest share of the market in 2021 and is likely to continue to register the highest CAGR in the market during the forecast period.
- The application segment is further segmented into fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy. The cancer therapy segment held the largest share of the market in 2022 and is likely to continue to register the highest CAGR in the market during the forecast period.
- The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The market in North America is projected to be the largest revenue share and is anticipated to maintain its dominance over the forecast period.
Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/liposome-drug-delivery-market
Liposome Drug Delivery Market Liposome Drug Delivery Market Regional Analysis
North America to Dominate the Market
- The market in North America is projected to be the largest revenue share and is anticipated to maintain its dominance over the forecast period.
- The growth of the market in the region can primarily be attributed to the increasing prevalence of cancer in the region, followed by the surge in government initiatives that promote research and development for cancer drugs and drug delivery systems, along with the surge in healthcare expenditure in the region.
Liposome Drug Delivery Market Competitive Landscape
- Johnson and Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
- Spectrum Pharmaceuticals
- Shanghai New Asia
Liposome Drug Delivery Market Recent Developments
- June 17th, 2020: Ipsen Pharma announced that it has received the Fast Track designation by the United States Food and Drug Administration (FDA) for the investigational use of liposomal irinotecan (ONIVYDE) in combination with oxaliplatin (OX) and 5-fluorouracil/leucovorin (5-FU/LV) together.
- December 9th, 2019: FUJIFILM Toyama Chemical Co., Ltd. announced that it has completed its first manufacturing facility named 701 for liposome formulation in Japan.
Reasons to Acquire in the Liposome Drug Delivery Market
- Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors.
- Gain authentic and granular data access for Liposome Drug Delivery Market so as to understand the trends and the factors involved behind changing market situations.
- Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
- In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
Direct Purchase of Liposome Drug Delivery Market Report Research Report: https://www.delvens.com/checkout/liposome-drug-delivery-market
Frequently Asked Questions
What are the years considered to study Liposome Drug Delivery Market intelligence report?
What is the compound annual growth rate (CAGR) of the Liposome Drug Delivery Market?
Which region holds the largest market share in Liposome Drug Delivery Market?
Which region is the fastest growing region in Liposome Drug Delivery Market?
Who are the major players in Liposome Drug Delivery Market?
Browse Related Reports:
Pendred Syndrome (PS) Market – Trends Forecast Till 2030
Pendred Syndrome (PS) Market by Treatment (Cochlear Implant, Hearing Aids, and Radioactive Iodine) Route of Administration (Oral, Implantation), Diagnosis (Genetic Testing, Perchlorate Washout Test, and Others), End- Users (Hospitals, Homecare, Specialty Clinics, Otolaryngologist, and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
Antacids Market – Trends Forecast Till 2030
Antacids Market, by Type (Sodium Antacids, Calcium Antacids, Magnesium Antacids Aluminium Antacids, Others), Indication (Gastroesophageal Reflux Disease, Heartburn, Indigestion, others), Dosage Form (Tablets, Liquid, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
Antibody Drug Conjugates (ADC) Market – Trends Forecast Till 2030
Antibody Drug Conjugates (ADC) Market, by Product Type (Adcetris, Kadcyla, and Other Product Types), Application (Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Other Applications), Technology (Cleavable Linker and Non-cleavable Linker), Target Type, End Users and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact Us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
